Metoprolol therapy improved ventricular function between months 1 and 3 (p=0.013) and reduced left ventricular mass from 333 to 275 g by 18 months (p=0.011).
RCT (n=26)
Blinded outcome assessment
Does metoprolol improve ventricular function, mass, and geometry over time in men with dilated cardiomyopathy?
26 men with dilated cardiomyopathy (congestive heart failure)
Metoprolol
Standard therapy for the first 3 months, followed by crossover to metoprolol
Time course of ventricular functional improvement, ventricular mass, and geometry measured by serial echocardiography at days 0 and 1, months 1 and 3, and late follow-upsurrogate
Metoprolol therapy in heart failure initially causes a mild reduction in systolic function, followed by improvement after 1 month and long-term reversal of maladaptive remodeling by 18 months.
p-value: p=0.013
OBJECTIVES: We examined the time course of ventricular functional improvement in patients with dilated cardiomyopathy who received beta-blockade and the long-term effects of beta-blockade on ventricular mass and geometry in these patients. BACKGROUND: Previous studies have shown that beta-adrenergic blocking agents when administered long term improve ventricular function in patients with heart failure. However, the time course of improvement in ventricular function and the long-term effects of beta-blockade on ventricular mass and geometry are not known. METHODS: Twenty-six men with dilated cardiomyopathy underwent serial echocardiography on days 0 and 1 and months 1 and 3 of either metoprolol (n = 16) or standard therapy (n = 10). At 3 months all patients on standard therapy were crossed over to metoprolol, and late echocardiograms were obtained after 18 +/- 5 (mean +/- SD) months of metoprolol therapy. All echocardiograms were read in blinded manner. RESULTS: Patients treated with metoprolol had an initial decline (day 1 vs. day 0) in ventricular function (increase in end-systolic volume and decrease in ejection fraction). Ventricular function improved between months 1 and 3 (p = 0.013, metoprolol vs. standard therapy). Left ventricular mass regressed at 18 months (333 +/- 85 to 275 +/- 53 g, p = 0.011) but not at 3 months. Left ventricular shape became less spherical and assumed a more normal elliptical shape by 18 months (major/minor axis ratio 1.5 +/- 0.2 to 1.7 +/- 0.2, p = 0.0001). CONCLUSIONS: Patients with heart failure treated with metoprolol do not demonstrate an improvement in systolic performance until after 1 month of therapy and may have a mild reduction in function initially. Long-term therapy with metoprolol results in a reversal of maladaptive remodeling with reduction in left ventricular volumes, regression of left ventricular mass and improved ventricular geometry by 18 months.
Building similarity graph...
Analyzing shared references across papers
Loading...
Shelley Hall
Heart Failure & Transplant
Carlos G. Cigarroa
Southwestern Medical Center
Lucille Marcoux
Cooper Institute
Journal of the American College of Cardiology
The University of Texas Southwestern Medical Center
United States Department of Veterans Affairs
Building similarity graph...
Analyzing shared references across papers
Loading...
Hall et al. (Sat,) conducted a rct in Dilated cardiomyopathy (n=26). Metoprolol vs. Standard therapy was evaluated on Ventricular function improvement between months 1 and 3 (p=0.013). Metoprolol therapy improved ventricular function between months 1 and 3 (p=0.013) and reduced left ventricular mass from 333 to 275 g by 18 months (p=0.011).
synapsesocial.com/papers/6a0933a50d00267143bfdce0 — DOI: https://doi.org/10.1016/0735-1097(94)00543-y
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: